Article

Diabetische Makulopathie

Der Ophthalmologe (Impact Factor: 0.53). 01/2010; 107(8):773-788. DOI: 10.1007/s00347-010-2202-z

ABSTRACT Trotz medikamentöser Fortschritte und teurer Präventionsprogramme steigt die Prävalenz der diabetischen Retinopathie, einer
der häufigsten Erblindungsursachen in Deutschland, aufgrund des demografischen Wandels weiter an. Nach wissenschaftlichem
Stand ist die „focal/grid“-Laserkoagulation, in Kombination mit der intravitrealen operativen Medikamentenapplikation (IVOM)
von VEGF-Inhibitoren (VEGF: „vascular endothelial growth factor“), zurzeit die wirksamste Therapie des klinisch signifikanten
Makulaödems mit Foveabeteiligung. Vitreomakuläre Interface-Anomalien erfordern den Einsatz der modernen Netzhautchirurgie.
Für die ischämische Makulopathie gibt es keine effektive Behandlung. Die zeitgemäße Einstellung des Blutzuckerspiegels und
die optimale Kontrolle relevanter Risikofaktoren haben in der interdisziplinären Abstimmung einen festen Stellenwert. Innovative
Entwicklungen in der pharmakologischen Therapie eröffnen eine optimistische Perspektive auf mögliche Funktionsverbesserungen,
die die Lebensqualität der Diabetespatienten steigern werden.

Due to demographic change the incidence of diabetic retinopathy has risen in spite of new facilities and prevention campaigns
and is still one of the leading causes of blindness in Germany. The combination of focal/grid laser photocoagulation and an
intravitreal anti-VEGF (vascular endothelial growth factor) regimen is the first line approach for clinically significant
macular edema with foveal involvement and is evidence-based. Vitreomacular interface abnormalities can be effectively treated
by modern vitreomacular surgery. Unfortunately, no proven treatment modality can be provided for ischemic maculopathy. The
management of systemic risks factors, such as hyperglycemia and arterial hypertension, remains a task of great importance
despite all modifications and increase of knowledge during recent years. Innovative developments in the field of intravitreal
pharmacotherapy have opened up new vistas. There are good prospects that modern ophthalmology will not be limited to preserving
visual function but to allow improvements and consequently enhance health-related quality of life for diabetic patients.

SchlüsselwörterDiabetische Makulopathie-Makulaödem-Laserkoagulation-Anti-VEGF-Therapie-HbA1c (Glykohämoglobin)
KeywordsDiabetic retinopathy-Macula edema-Laser photocoagulation-Anti-VEGF therapy-HbA1c (glycohemoglobin)

0 Bookmarks
 · 
65 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To compare ranibizumab with focal/grid laser or a combination of both in diabetic macular edema (DME). Prospective, randomized, interventional, multicenter clinical trial. A total of 126 patients with DME. Subjects were randomized 1:1:1 to receive 0.5 mg of ranibizumab at baseline and months 1, 3, and 5 (group 1, 42 patients), focal/grid laser photocoagulation at baseline and month 3 if needed (group 2, 42 patients), or a combination of 0.5 mg of ranibizumab and focal/grid laser at baseline and month 3 (group 3, 42 patients). The primary end point was the change from baseline in best-corrected visual acuity (BCVA) at month 6. At month 6, the mean gain in BCVA was significantly greater in group 1 (+7.24 letters, P = 0.01, analysis of variance) compared with group 2 (-0.43 letters), and group 3 (+3.80 letters) was not statistically different from groups 1 or 2. For patients with data available at 6 months, improvement of 3 lines or more occurred in 8 of 37 (22%) in group 1 compared with 0 of 38 (0%) in group 2 (P = 0.002, Fisher exact test) and 3 of 40 (8%) in group 3. Excess foveal thickness was reduced by 50%, 33%, and 45% in groups 1, 2, and 3, respectively. During a span of 6 months, ranibizumab injections by the current protocol had a significantly better visual outcome than focal/grid laser treatment in patients with DME.
    Ophthalmology 09/2009; 116(11):2175-81.e1. · 5.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Diabetic retinopathy (DR) is a leading cause of vision loss in the working-age population worldwide. Many observational and preclinical studies have implicated vascular endothelial growth factor (VEGF) in the pathogenesis of DR, and recent successes with anti-VEGF therapy for age-related macular degeneration (AMD) have prompted research into the application of anti-VEGF drugs to DR. Here we review the numerous early studies that suggest an important potential role for anti-VEGF agents in the management of diabetic retinopathy. CONCLUSIONS: For diabetic macular edema, phase II trials of intravitreal pegaptanib and intravitreal ranibizumab have shown short-term benefit in visual acuity. Intravitreal bevacizumab also has been shown to have beneficial short-term effects on both visual acuity and retinal thickness. For proliferative diabetic retinopathy (PDR), early studies suggest that intravitreal bevacizumab temporarily decreases leakage from diabetic neovascular lesions, but this treatment may be associated with tractional retinal detachment (TRD). Furthermore, several studies indicate that bevacizumab is likely to prove a helpful adjunct to diabetic pars plana vitrectomy (PPV) for TRD. Finally, three small series suggest a potential beneficial effect of a single dose of bevacizumab to prevent worsening of DME after cataract surgery. Use of anti-VEGF medications for any of these indications is off-label. Despite promising early reports on the safety of these medications, we eagerly await the results of large, controlled trials to substantiate the safety and efficacy of anti-VEGF drugs for diabetic retinopathy.
    Albrecht von Graæes Archiv für Ophthalmologie 02/2010; 248(7):915-30. · 1.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diabetic retinopathy is a highly prevalent cause of visual loss in Western countries. Vascular endothelial growth factor (VEGF) is a potent angiogenic factor implicated in the development of the proliferative stage of this disease. Reports have suggested that polymorphisms at positions -460 and -634 of the 5' untranslated region of the VEGF gene increase its basal promoter activity. To investigate whether polymorphisms are associated with diabetic retinopathy, 215 patients with type 2 diabetes mellitus (T2DM) were enrolled. Among them, 82 subjects had proliferative diabetic retinopathy (PDR), 72 had non-proliferative diabetic retinopathy (NPDR), and 61 individuals without retinopathy served as controls. Two polymorphisms of the VEGF gene, a G-->C transversion at -634 (the G/C polymorphism) and a C-->T transition at -460 (the C/T polymorphism), were investigated by restriction fragment length polymorphism PCR and allele-specific PCR respectively. We did not find any association between the C/T polymorphism and diabetic retinopathy. However, the G/C polymorphism genotype distribution and the frequency of the C allele were significantly higher in the NPDR group than in control patients (OR = 1.69, 95% CI = 1.03-2.79). Analysis of the distribution of combined genotypes of the VEGF gene revealed the prevalence of the C/C-C/C genotype in NPDR patients (OR = 8.26, 95% CI = 1.79-37.99) and C/G-CC in PDR patients (OR = 3.36, 95% CI = 1.39-8.12). Occurrence of the -634C allele appears to be associated with increased VEGF gene promoter activity, and the G/C polymorphism might serve as a predictive factor for the development of diabetic retinopathy.
    Albrecht von Graæes Archiv für Ophthalmologie 01/2008; 246(1):39-43. · 1.93 Impact Factor